Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CSF shunts cases in Washington: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (47 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 174 | 37% |
| 2020 | 0 | 127 | 40% |
| 2021 | 2 | 154 | 43% |
Ventriculoperitoneal shunt placement and revision, including normal-pressure hydrocephalus. Professional codes (what the surgeon bills): CPT 62223, 62230.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Washington; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 11 | 827+0.6%/yr | +0.6%/yr | 0.2 | 0% | 910 in 2030+1.5%/yr |
| Arizona | 3 | 152−8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Aneurysm & intracranial embolization | 12 | 398+16%/yr | +16%/yr | 0.51.1× | 0% | 840 in 2030+13%/yr |
| DBS & VNS |
CSF shunts in every state, and its device makers · Every procedure market in Washington · Every state · Compare with California
| ≈ 140 |
| – |
| 2026 est. | ≈ 140 | – |
| 2022 | 1 | 131 | 46% |
| 2023 | 0 | 142 | 50% |
| 2024 | 1 | 140 | 54% |
| 2025 from claims | – | 140 113–164 | 54% |
| 2026 forecast | – | 142 111–178 | 54% |
| 2027 forecast | – | 142 105–188 | 55% |
| 2028 forecast | – | 142 101–196 | 56% |
| 2029 forecast | – | 142 97–204 | 57% |
| 2030 forecast | – | 142 93–211 | 57% |
In 2025, 100% inpatient hospital.
| −8%/yr |
| 0.2 |
| 0% |
| 170 in 2030+1.6%/yr |
| 6 |
| 357−1.8%/yr |
| −1.8%/yr |
| 0.51.5× |
| 0% |
| 290 in 2030−3.1%/yr |
| Stroke thrombectomy | 12 | 317+1.2%/yr | +1.2%/yr | 0.41.1× | 0% | 270 in 2030−2.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Integra LifeSciences leads with 38% of company spending on these surgeons in 2025, +35 pts on 2024.
In 2025, 5 companies reported engagement with Washington’s surgeons worth $3,148 in consulting, speaking, meals and travel tied to these products, about $3,148 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.